INFINITI BRAF Assay

  • The INFINITI BRAF Assay is CE Marked.
  • The INFINITI BRAF is designed to identify genetic mutations of the BRAF gene.
  • The INFINITI BRAF utilizes the BRAF Intellipac, BRAF Amp Mix and BRAF BioFilmChip Microarray.
  • The INFINITI BRAF Assay is automated by the INFINITI Analyzer.

Analytes Detected: 
  • Codon 600: V600A, V600D, V600E, V600KRM
Features: 
  • Multiplexed determination of 4 genetic variants on one BioFilmChip Microarray
  • Customized reports
  • Load & Go automated on the INFINITI/INFINITI PLUS Analyzer.
  • Replicate determinations on a single BioFilmChip Microarray ensures quality results.

Sample Type and Volume: 
  • Uses formalin-fixed and paraffin-embedded (FFPE) tissue samples.
  • Requires 25-50ng DNA/reaction
Clinical Relevance: 
  • BRAF mutations are present in about 12% of carcinomas
  • Common in the following cancers:
  •      Colorectal
  •      Melanomas
  •      Thyroid
  • Mutations may indicate prognosis and drug response to Cancer therapies (anti-EGFR  drugs – Cetuximab/Erbitux, Panitumumab/Vectibix, Gefitinib/Iressa, Erlotinib/Tarceva).
Clinical Utility: 
  • Identification of BRAF mutations suggests that anti-EGFR therapies will not work in most, if not all patients.
  • Presence of BRAF mutations also suggests prognosis for Thyroid cancer and Melanomas.
References: 
  1. Garnett MJ, Marais R (2004). "Guilty as charged: B-Raf is a human oncogene". Cancer Cell 6 (4): 313–9. doi:10.1016/j.ccr.2004.09.022. PMID 15488754. 
  2. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X (2005). "Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations". Cancer 103 (11): 2261–8. doi:10.1002/cncr.21073. PMID 15880523.

INFINITI BRAF Assay